Page last updated: 2024-11-12

gsk 1034702

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

GSK 1034702: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16038386
CHEMBL ID5095238
SCHEMBL ID3389353
MeSH IDM0569128

Synonyms (20)

Synonym
SCHEMBL3389353
2h-benzimidazol-2-one, 4-fluoro-1,3-dihydro-6-methyl-1-(1-(tetrahydro-2h-pyran-4-yl)-4-piperidinyl)-
gsk1034702
1449521-40-7
gsk 1034702 [who-dd]
4-fluoro-6-methyl-1-[1-(tetrahydro-2h-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2h-benzimidazol-2-one
KRRSQJOVDWYKHH-UHFFFAOYSA-N
n9c1c7xl4e ,
gsk-1034702
unii-n9c1c7xl4e
932373-87-0
4-fluoro-6-methyl-1-(1-(tetrahydro-2h-pyran-4-yl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one
gsk 1034702
Q27284740
qk2 ,
7-fluoranyl-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1~{h}-benzimidazol-2-one
CS-0027342
HY-107111
AKOS040748454
CHEMBL5095238

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In a clinical trial, a strong drug-drug interaction (DDI) was observed between dextromethorphan (DM, the object or victim drug) and GSK1034702 (the precipitant or perpetrator drug), following single and repeat doses."( Retrospective use of PBPK modelling to understand a clinical drug-drug interaction between dextromethorphan and GSK1034702.
Bloomer, J; Dear, G; Hobbs, MJ, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]